Item 8.01 Other Events.

On January 27, 2022, the Company issued a press release announcing that China's National Medical Products Administration (NMPA) has accepted submission of a New Drug Application (NDA) for oliceridine injection. The NDA was submitted by Trevena's partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa of a Phase 3 bridging trial for OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved in the United States by the Food and Drug Administration (FDA) for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.






 (d) Exhibits




Number                                      Description
  99.1       Press Release dated January 27, 2022
104        The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

© Edgar Online, source Glimpses